drugset
Drugs / Stem Cell
last change Feb 2026 re-read 2 minutes ago

Stem Cell

also known as mononuclear cell

Cell therapy

Developed for
Duchenne muscular dystrophy · primary ovarian failure · amyotrophic lateral sclerosis · limb-girdle muscular dystrophy · muscular dystrophy · nervous system disorder · pilonidal sinus · post-COVID-19 disorder
+2 more · stroke disorder · diabetic neuropathy
Investigated by
Neurogen Brain and Spine Institute · Al-Azhar University · CBR Systems, Inc. · Chaitanya Hospital, Pune · Charles Cox · Mustafa Azizoğlu
+1 more · Necmi Kadıoğlu Hospital

Trials 11 · a red edge is where a trial was stopped

today NCT06391307 · not/applicable NCT06156241 · Ph 1 NCT01834066 · Ph 1/2 NCT02372474 · Ph 1/2 NCT02151890 · Ph 1/2 NCT02245711 · Ph 1 NCT02241434 · Ph 1 NCT02241928 · Ph 1 NCT02245776 · Ph 1 NCT02245698 · Ph 1 NCT02242071 · Ph 1
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT06156241 Jan 2024 → Dec 2025 post-COVID-19 disorder Charles Cox Unknown No outcome recorded
Phase 1 NCT02245711 Dec 2010 → Jan 2015 limb-girdle muscular dystrophy Neurogen Brain and Spine Institute Withdrawn No outcome recorded
Phase 1 NCT02241434 Jan 2009 → Jan 2016 Duchenne muscular dystrophy Neurogen Brain and Spine Institute Withdrawn No outcome recorded
Phase 1 NCT02241928 Jan 2009 → Dec 2018 muscular dystrophy Neurogen Brain and Spine Institute Withdrawn No outcome recorded
Phase 1 NCT02245776 Dec 2008 → Jun 2018 nervous system disorder Neurogen Brain and Spine Institute Withdrawn No outcome recorded
Phase 1 NCT02245698 Dec 2008 → Jun 2018 stroke disorder Neurogen Brain and Spine Institute Withdrawn No outcome recorded
Phase 1 NCT02242071 Dec 2008 → Mar 2015 amyotrophic lateral sclerosis Neurogen Brain and Spine Institute Withdrawn No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT01834066 Sep 2014 → Nov 2016 Duchenne muscular dystrophy Chaitanya Hospital, Pune Unknown No outcome recorded
Phase 1/2 NCT02372474 Mar 2012 → Dec 2014 primary ovarian failure Al-Azhar University Completed No outcome recorded
Phase 1/2 NCT02151890 Mar 2012 → May 2014 primary ovarian failure Al-Azhar University Completed No outcome recorded
Phase not applicable1 trial
— NCT06391307 May → Nov 2024 pilonidal sinus Mustafa Azizoğlu Unknown No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
— NCT02315235 Comparator May 2014 → Mar 2016 diabetic neuropathy Seoul National University Hospital Withdrawn No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as Stem Cell ClinicalTrials.gov intervention name — accepted as the source's own label NCT01834066 ↗
11

NCT02315235 ↗

NCT02241928 ↗

NCT02241434 ↗

NCT02245711 ↗

NCT02372474 ↗

NCT02242071 ↗

NCT06156241 ↗

NCT02245698 ↗

NCT02245776 ↗

NCT06391307 ↗

NCT02151890 ↗
Known as mononuclear cell “The stem-cell (mononuclear cell) is injected into the muscle in the other side leg of patient.” NCT02315235 ↗
Modality Cell therapy “Intra thecal transplantation of autologous Stem Cell MNCs” NCT01834066 ↗
Route Intrathecal “Intra thecal transplantation of autologous Stem Cell MNCs” NCT01834066 ↗